Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 11/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373143 | 0.81 | CFTR (0.39) | CFTRHDAC1ADORA2AITK | |
| SCHEMBL2373061 | 0.79 | NAMPT (0.40) | HPGDSCFTRHDAC1PIK3CA | |
| SCHEMBL2373130 | 0.79 | CFTR (0.40) | CFTRHDAC1ADORA2A | |
| SCHEMBL2372384 | 0.77 | HPGDS (0.40) | HPGDSCFTRHDAC1ADORA2A | |
| SCHEMBL14784270 | 0.73 | CFTR (0.42) | CFTRP2RX7 | |
| SCHEMBL2371638 | 0.73 | HDAC2 (0.50) | CFTRADORA2A | |
| SCHEMBL2373116 | 0.72 | KDM4E (0.57) | — | |
| SCHEMBL29699246 | 0.72 | KDM4E (0.57) | — | |
| SCHEMBL12460029 | 0.71 | KMT2A (0.65) | KMT2AL3MBTL1HPGDSP2RX7ITK | |
| SCHEMBL29699276 | 0.71 | CD274 (0.51) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| CN-113891744-A | Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis | 诺华股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-11-06 | — | — | US | disclosed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | disclosed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8476269-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2547656-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | KMT2A 4067/4885L3MBTL1 3922/4885HPGDS 995/4885 |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | KMT2A 4007/4885L3MBTL1 3866/4885HPGDS 1082/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | KMT2A 4067/4885L3MBTL1 3922/4885HPGDS 995/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | KMT2A 4133/4885L3MBTL1 3936/4885HPGDS 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.